Zemler / Shutterstock.com
19 December 2014Big PharmaTrevor Cook
Marketing authorisation: the right to challenge
Since the EU regime of data exclusivity for pharmaceuticals was amended in late 2005, in large part to reflect Court of Justice of the EU (CJEU) case law in the 1990s and early 2000s, there has been little case law on the interpretation of the new legislation. This situation is now starting to change.
